Advancing Therapies Where Metabolism Begins

Our HDV™ platform supports a growing pipeline of therapies designed to overcome limitations in today’s most-used metabolic treatments—addressing unmet patient needs in diabetes, obesity, and other cardiometabolic diseases with targeted precision.

Scientist holding vials in a lab

Our Pipeline

Diasome’s pipeline is focused on advancing therapies across three key areas:

  • HDV Mealtime Insulin

    Type 1 Diabetes
    Type 2 Diabetes
    S.C. Injectable

    OPTI-2, HDV-Rapid Acting Insulin

    Phase 2B Complete

    OPTI-2, Injectable HDV-Rapid Acting Insulin

    HDV-Rapid Acting Insulin Open Label, Mechanism of Action

      Phase 2

    Injectable HDV-Rapid Acting Insulin Open Label, MoA

    Preclinical
    Phase 2
    PHase 2B
    Phase 3

    Best-in-class Mealtime Insulin

    By directing insulin to the liver, HDV is designed to restore physiologic glucose regulation at mealtime. This liver-targeted approach has been shown to reduce hypoglycemia, improves post-prandial predictability and expands the therapeutic window of rapid-acting insulin.

    ‍

    Next anticipated milestone: Phase 3 study initiation
    View the Clinical Trial

  • HDV-GLP-1 and GLP-1/GIP Program

    Type 2 Diabetes
    S.C. Injectable

    HDV-GLP-1,
    Novel Mechanism

    Preclinical

    Oral HDV-Serotonin, 
Novel Mechanism

    Preclinical
    Phase 2
    PHase 2B
    Phase 3

    Using HDV targeted incretins to access the Gut-Liver-Brain axis

    Intestinal-derived GLP-1 plays an important role in several metabolic processes including brain-mediated satiety signaling and appetite regulation. By targeting GLP-1 to the portal vein we expect to improve efficacy in fat, glucose and weight endpoints, while mitigating off-target side effects.

    ‍

    Next anticipated milestone: IND filing
    View the Clinical Trial

  • HDV-Serotonin Program

    Type 2 Diabetes
    ORAL
                           

    HDV-Serotonin,
    Novel Mechanism

    Preclinical

    Injectable HDV-GLP-1, Novel Mechanism

    Preclinical
    Phase 2
    PHase 2B
    Phase 3

    Addressing Insulin Resistance in Type 2 Diabetes

    A novel, first-in-class oral therapy designed to replace declining or deficient portal-hepatic serotonin levels, enabling hepatic utilization of insulin.

    ‍

    Next anticipated milestone: Tox study completion
    View the Clinical Trial